Management Team


Greg Mullen
Chief Executive Officer

Greg Mullen is the Chief Executive Officer of Theragnostics Limited and President of Theragnostics Inc. Greg is a founding member of Theragnostics since its formation in 2015.

Greg graduated with a PhD in Chemistry from the University of Kent and went on to Oxford University where he completed his post-doctoral research. Greg has a career spanning over 20-years in translational medicine. He has extensive product and clinical development experience across a range of small molecule and biological products. He has taken vaccines from discovery through to pediatric Phase 2b clinical trials while at the National Institutes of Health in the United States. In 2007, Greg joined the Department of Imaging Chemistry and Biology at King’s College London and his research group developed several imaging diagnostics for precision medicine in autoimmunity, heart disease and oncology. It was during this time that he co-invented the novel Ga-68 radiopharmaceutical chelator which enabled the development of cold PET kits. In 2012 Greg joined Oxford Immunotec as Research and Development Director where he was responsible for expanding their diagnostic product pipeline in chronic infections and autoimmunity. Greg went on to become Chief Scientific Officer at Mediso Ltd where he developed cancer specific imaging procedures to achieve high quality and accurate data to enable better diagnosis of cancer.

At Theragnostics, Greg has been instrumental in raising capital via grant funding and private investment.


Image Coming Soon

Alex Jackson
Head R&D

Alex Jackson is the Head of R&D at Theragnostics and has 20 years’ experience in the field of radiopharmaceutical R&D. He completed a PhD in Chemistry at Warwick University with a focus on supramolecular and medicinal chemistry.
Alex started his career at Amersham Health (later acquired by GE Healthcare) as a medicinal chemist, transitioning to radiopharmaceutical chemistry as a senior scientist in 2008. He has expertise across a broad range of radiopharmaceutical sciences applicable to early discovery through to late stage clinical-phase projects. During his time at GE, Alex was also heavily involved in the assessment of new technology, licensing opportunities and intellectual property.

At Theragnostics, Alex’s primary responsibility is the CMC development of pipeline assets, management of strategic partnerships and the identification and assessment of new opportunities.



Management Team


Greg Mullen

Chief Executive Officer

Greg Mullen is the Chief Executive Officer of Theragnostics Limited and President of Theragnostics Inc. Greg is a founding member of Theragnostics since its formation in 2015.

Greg graduated with a PhD in Chemistry from the University of Kent and went on to Oxford University where he completed his post-doctoral research. Greg has a career spanning over 20-years in translational medicine. He has extensive product and clinical development experience across a range of small molecule and biological products. He has taken vaccines from discovery through to pediatric Phase 2b clinical trials while at the National Institutes of Health in the United States. In 2007, Greg joined the Department of Imaging Chemistry and Biology at King’s College London and his research group developed several imaging diagnostics for precision medicine in autoimmunity, heart disease and oncology. It was during this time that he co-invented the novel Ga-68 radiopharmaceutical chelator which enabled the development of cold PET kits. In 2012 Greg joined Oxford Immunotec as Research and Development Director where he was responsible for expanding their diagnostic product pipeline in chronic infections and autoimmunity. Greg went on to become Chief Scientific Officer at Mediso Ltd where he developed cancer specific imaging procedures to achieve high quality and accurate data to enable better diagnosis of cancer.


At Theragnostics, Greg has been instrumental in raising capital via grant funding and private investment.


Image Coming Soon

Dr. Alex Jackson, PhD

Head R&D

Alex Jackson is the Head of R&D at Theragnostics and has 20 years’ experience in the field of radiopharmaceutical R&D. He completed a PhD in Chemistry at Warwick University with a focus on supramolecular and medicinal chemistry.
Alex started his career at Amersham Health (later acquired by GE Healthcare) as a medicinal chemist, transitioning to radiopharmaceutical chemistry as a senior scientist in 2008. He has expertise across a broad range of radiopharmaceutical sciences applicable to early discovery through to late stage clinical-phase projects. During his time at GE, Alex was also heavily involved in the assessment of new technology, licensing opportunities and intellectual property.

At Theragnostics, Alex’s primary responsibility is the CMC development of pipeline assets, management of strategic partnerships and the identification and assessment of new opportunities.